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Background: The development of techniques that allow the imaging of animals infected with parasites expressing
luciferase opens up new possibilities for following the fate of parasites in infected mammals.
Methods: D-luciferin potassium salt stock solution was prepared in phosphate-buffered saline (PBS) at 15 mg/ml.
To produce bioluminescence, infected and control mice received an intraperitoneal injection of luciferin stock solution
(150 mg/kg). All mice were immediately anesthetized with 2% isofluorane, and after 10 minutes were imaged.
Ex vivo evaluation of infected tissues and organs was evaluated in a 24-well plate in 150 μg/ml D-luciferin diluted
in PBS. Images were captured using the IVIS Lumina image system (Xenogen). Dissected organs were also evaluated by
microscopy of hematoxylin-eosin stained sections.
Results: Here we describe the results obtained using a genetically modified Dm28c strain of T. cruzi expressing the
firefly luciferase to keep track of infection by bioluminescence imaging. Progression of infection was observed in vivo in
BALB/c mice at various intervals after infection with transgenic Dm28c-luc. The bioluminescent signal was immediately
observed at the site of T. cruzi inoculation, and one day post infection (dpi) it was disseminated in the peritoneal cavity.
A similar pattern in the cavity was observed on 7 dpi, but the bioluminescence was more intense in the terminal region
of the large intestine, rectum, and gonads. On 14 and 21 dpi, bioluminescent parasites were also observed in the heart,
snout, paws, hind limbs, and forelimbs. From 28 dpi to 180 dpi in chronically infected mice, bioluminescence declined
in regions of the body but was concentrated in the gonad region. Ex vivo evaluation of dissected organs and tissues
by bioluminescent imaging confirmed the in vivo bioluminescent foci. Histopathological analysis of dissected organs
demonstrated parasite nests at the rectum and snout, in muscle fibers of mice infected with Dm28c-WT and with
Dm28c-luc, corroborating the bioluminescent imaging.
Conclusion: Bioluminescence imaging is accurate for tracking parasites in vivo, and this methodology is important to
gain a better understanding of the infection, tissue inflammation, and parasite biology regarding host cell interaction,
proliferation, and parasite clearance to subpatent levels.
Keywords: Trypanosoma cruzi, Luciferase, Bioluminescence, Testicles, Rectum, Heart, Mice, Chagas disease* Correspondence: wsouza@biof.ufrj.br
1Laboratório de Ultraestrutura Celular Hertha Meyer, Instituto de Biofísica
Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, CCS-Bloco G,
Ilha do Fundão, 21941-900 Rio de Janeiro-RJ, Brazil
2Instituto Nacional de Ciência e Tecnologia em Biologia Estrutural e
Biomagens-INBEB, Janeiro-RJ, Brazil
Full list of author information is available at the end of the article
© 2014 Henriques et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public
Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this
article, unless otherwise stated.
Henriques et al. Parasites & Vectors 2014, 7:89 Page 2 of 15
http://www.parasitesandvectors.com/content/7/1/89Background
Trypanosoma cruzi is the etiological agent of Chagas
disease, a debilitating illness that still causes 10,000 to
14,000 deaths per year and affects millions of people in
Central and South America, where 8 to 10 million people
are infected [1]. T. cruzi has a complex life cycle that
involves the following three developmental stages: amasti-
gote (intracellular replicative form in vertebrate host),
epimastigote (extracellular replicative form found in the
gut of invertebrate host), and trypomastigote (infective
form for vertebrate hosts) [2]. It has been shown that
T. cruzi is able to infect all nucleated mammalian cells
in culture. In vivo it has been shown that even adipocytes
can be infected by trypomastigotes [3]. However, cells
of the reticuloendothelial, nervous and muscle systems
appear to be the preferential ones in the experimental
model and in T. cruzi-infected individuals [4,5].
For a more complete understanding of the tissue
distribution of T. cruzi in the entire animal and the
evolution of the infection during the course of analysis
of new anti-parasite drugs, it is important to establish
experimental models in which the parasites can be
easily followed within the animal. Currently available
chemotherapeutic agents for Chagas disease are nifur-
timox and benznidazole. Although both are active in
the acute phase, their efficacy is very limited during
the chronic phase. In addition, both drugs demonstrate
poor activity against many T. cruzi isolates, and have
considerable side effects that can lead to the discontinuity
of the therapy [6]. In recent years, several studies
attempted to identify selective metabolic targets for
new drugs, making this a very active area of research.
Enzymes and metabolic pathways found by proteomic,
transcriptomic, and metabolomic analysis [7-9], coupled
with platforms of drug design, necessitate more advanced
methods of screening compounds in vivo. Novel method-
ologies and technologies have been developed for in vitro
screening of compounds with inhibitory activity against
protozoa, such as viability and proliferative assays [10].
This includes the use of transgenic parasites expressing
fluorescent proteins and/or luciferase, in conjunction with
sensitive imaging systems and instruments.
The bioluminescent imaging represents an innovation
in pre-clinical evaluation of drugs in vivo and in the
follow-up of infection in small mammals. The foci of
infection can be tracked throughout the body in real
time, as long as the animal is alive. This noninvasive
technology gives light to the new sites of infection that
could not be observed easily through histological tech-
niques and allows investigators to evaluate the dynamic
of parasite distribution in the whole body, a methodology
that does not require killing the animal to evaluate
infected tissues. Some studies on standardization of this
important technological tool, using Trypanosoma cruzi,Leishmania sp, and Toxoplasma gondii, have shown its
application [11-14]. We previously described the use of
bioluminescence imaging to follow the fate of T. cruzi
in the invertebrate host [12]. In the present work, we
explored, using a bioluminescent imaging system, the
progression of the infection in mice infected with trans-
genic Dm28c-luc strain of Trypanosoma cruzi expressing
luciferase. It was possible to monitor in real time the
progression of infection in the same group of infected
mice. This innovative technology enabled a better evalu-
ation of the acute infection, including the discovery of
tissues and organs with intense parasitism during the
course of experimental infection up to the chronic phase
of the disease. Bioluminescent imaging is a powerful tool
for the evaluation of the effect of anti-parasite compounds
on the evolution of ongoing biological processes in live
mammals and other organisms.
Methods
Parasites
We used wild type Dm28c clone(Dm28c-WT) of T. cruzi
and genetically modified parasites expressing luciferase
(Dm28c-luc) (description below). Epimastigote forms of
both strains were cultivated in liver infusion tryptose
(LIT) medium supplemented with 10% fetal calf serum
(FCS) at 28°C up to the logarithmic stage of growth
[15]. Metacyclic trypomastigote forms were then obtained
in vitro by subjecting T. cruzi epimastigotes from the late
exponential growth phase (at cell density of 3 × 107 cells/ml)
to nutritional stress in triatomine artificial urine (TAU)
medium (190 mM NaCl, 8 mM phosphate buffer, 17 mM
KCl, 2 mMMgCl2, pH 6.0) for 2 hours. Metacyclic parasites
were further cultivated for five days in TAU medium
supplemented with amino acids and glucose (TAU3AAG)
(TAU supplemented with 0.035% sodium bicarbonate,
10 mM L-proline, 50 mM sodium glutamate, 2 mM sodium
L-aspartate, and 10 mM glucose) [16]. Metacyclic parasites
were used to infect LLC-MK2 cells and trypomastigote
forms released from cell cultures were used to infect mice.
Intracellular amastigotes and amastigotes were obtained
from LLC-MK2 cells infected with trypomastigotes and
cultivated for 5 to 10 days in RPMI 1640 medium supple-
mented with 5% FCS at 37°C in a 5% CO2 atmosphere.
Dm28c-luc trypomastigotes and/or amastigotes of cell
culture, maintained in culture for 5 months without G418,
were differentianted back to epimastigotes after incubation
in LIT medium supplemented with 10% FCS at 28°C.
Bioluminescence in epimastigotes were evaluated in a
microplate reader Spectra Max2.
Infection rate
LLC-MK2 cells were plated on 13 mm round glass cov-
erslips in a 24 well microplate, maintained for 18 hours
in RPMI 1640 medium with 5% FBS at 37°C in a 5%
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allowed to interact with trypomastigotes of Dm28c-WT
or Dm28c-luc with a parasite-host cell ratio of 10:1, in
200 μl of RPMI at 37°C in a 5% CO2 atmosphere. After
4 hours, cultures were washed to remove non-internalized
parasites and maintained in RPMI 1640 medium with
5% FBS at 37°C in a 5% CO2 atmosphere for 24, 48 and
72 hours. Infected cells were fixed with Bouin, washed
with 70% ethanol, water and stained with Giemsa. Sub-
sequently, coverslips were dehydrated in acetone–xylol
(100% acetone; 70% acetone – 30% xylol; 30% acetone–
70% xylol; 100% xylol) and sealed with Entelan® (Merck).
The percentage of infection and number of parasites per
infected cells were quantified in at least 500 cells in a light
microscope (Leica Microsystems). Two independent exper-
iments were performed in triplicate.
Animals and infection
Seven-week-old male BALB/c mice were obtained from
the Animal Laboratory Breeding Center at Fundação
Oswaldo Cruz (CECAL) and housed for 7 days in the
Laboratory of Cellular Ultrastructure at UFRJ under
environmental and sanitation conditions established in
the guide for the Care and Use of Laboratory Animals
(DHEW publication No. [NIH] 80–23). This project was
approved by the Biophysics Institution Committee of
Ethics in Animal Research (IBCCF106), according to
resolution 196/96 of the National Health Council of the
Brazilian Ministry of Health. Experimental groups were
composed of five mice, which were intraperitoneally
infected with 1 × 106 or 1 × 105 Dm28c-WT or Dm28c-
luc parasites in 200 μl of RPMI medium. Parasitemia
was determined in 5 μl of blood obtained from tail
snips, according to the Pizzi-Brenner method [17].
Expression of firefly luciferase (Fluc) in Trypanosoma cruzi
The luciferase gene was amplified by PCR using specific
primers, the forward containing an XbaI site and the
kozak sequence upstream from the start codon (italics),
5′-GCTCTAGA GCCACC ATGGAAGACGCCAAAAA
CATAAAG–3′ (F-luc), and the reverse primer containing
an XhoI site (italic) 5′-CCGCTCGAG CGGTTACAC
GGCGATCTTTCC-3′ (R-luc), using the Tli DNA Poly-
merase (Promega) and the following PCR conditions:
94°C, 5 min; 94°C, 30 sec; 60°C, 30 sec; 72°C, 2 min, 30 cy-
cles; 72°C, 10 min. The PCR product was cloned into the
Zero Blunt TOPO PCR Cloning Kit (Invitrogen), digested
from the TOPO vector, and subcloned into the integrative
pTREX vector at the XbaI and XhoI restriction sites [18].
The construction was sequenced on an ABI 3730 Genetic
Analyzer (Applied Biosystems) using the sequencing plat-
form installed at the Oswaldo Cruz Foundation (Fiocruz).
T. cruzi epimastigote forms of Dm28c clone (Dm28c-
WT) were suspended at 1 × 108 cells/mL in electroporationbuffer (EPB) containing 137 mM NaCl; 5 mM KCl; 0.7 mM
Na2HPO4; 6 mM glucose; 21 mM HEPES, pH 7.3. The
cellular suspension (400 μl) was mixed with 50 μg of
plasmid, placed in a 0.2 cm cuvette and subjected to a
pulse of 0.45 kV, 500 μF at room temperature in a Gene
Pulser apparatus (BioRad Laboratories) [19]. The parasites
were resuspended in LIT medium and stable transfor-
mants were selected with 200 to 500 μg/mL of G418.
Thereafter, positive epimastigotes were selected by serial
dilution in a 96 plate, and selected by bioluminescence
emission with SteadyGlo reagent (Promega) in a Spectra-
Max2 microplate reader.In vitro bioluminescent imaging
To perform a bioluminescent curve of intracellular
Dm28c-luc amastigotes, LLC-MK2 cells (103) were plated
in a 96 well microplate and maintained for 18 hours in
RPMI 1640 medium with 5% FBS at 37°C in a 5% CO2
atmosphere. Afterwards, the cells were washed and allowed
to interact with 102 to 104 trypomastigotes of Dm28c-
luc. Infected cells were cultivated for 24 to 48 hours in
RPMI 1640 medium with 5% FBS at 37°C in a 5% CO2
atmosphere. Bioluminescent images were obtained from
trypomastigotes, and from intracellular parasites, after 24
and 48 hours of cultivation. Images were acquired after
5 minutes of incubation of trypomastigotes with 150 μg/ml
of D-luciferin in 200 μl of RPMI medium in a black 96
well microplate. Intracellular amastigotes were removed
from the plate with 50 μl of SteadyGlo reagent (Promega),
transferred to the 96 well black microplate and the volume
adjusted to 200 μl of RPMI with 150 μg/ml of D-luciferin.
Bioluminescence was quantified with automatic measure-
ment ROI.In vivo bioluminescent imaging
The infection with transgenic parasites was also monitored
over time by detecting the bioluminescence in the whole
animal using the IVIS Lumina image system (Xenogen).
The equipment consists of a cooled charge-coupled cam-
era mounted on a light-tight chamber with a nose cone
delivery device to keep the mice anesthetized during image
acquisition (IVIS 100; Xenogen). D-luciferin potassium salt
(Xenogen) stock solution was prepared in phosphate-
buffered saline (PBS) at 15 mg/ml, filter-sterilized, and
stored in a-80° freezer. To produce bioluminescence, mice
infected with Dm28c-luc and infected with Dm28c-WT
received an intraperitoneal injection of D-luciferin stock
solution (150 mg/kg). All mice were immediately anesthe-
tized in an oxygen-rich induction chamber with 2%
isofluorane, and images were captured after 10 minutes
incubation to allow substrate distribution. Mice in-
fected with Dm28c-WT were injected with D-luciferin
(150 mg/kg) or PBS and submitted to the same procedure
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after 1 hour and 24 hours post infection (1 dpi).
Bioluminescent images were obtained after 1 hour, at
1, 4 to 28, and 180 dpi (chronic phase). Bioluminescent
images were obtained of mice in dorsal, ventral, and lateral
position. Anesthesia was maintained during the entire
imaging process by using a nose cone isofluorane-oxygen
delivery device in the light-tight chamber.
To acquire the bioluminescent images, some parameters
were considered based on the level of bioluminescent
emission, such as the time of exposure, which ranged from
a few seconds to 5 minutes, the number of pixels, and the
field of view (FOV) with automatic focus. The Living
Image software automatically co-registered the lumines-
cent images, which were taken in darkness and displayed
in pseudo-colors that represent the intensity of the signal
and the photographic image, generating an overlay image.
Ex vivo bioluminescent imaging
Mice infected with 1 × 105 Dm28c-luc trypomastigote
forms were euthanized at 14, 21, 28, and 180 dpi
(6 months), and selected organs were excised. The bio-
luminescence in infected tissues and organs was evaluated
in a 24-well plate or in individual plates in 150 μg/ml
D-luciferin diluted in enough volume of PBS, to cover
the tissues, 0.5 ml for 24 well plate and 1 to 2 ml in in-
dividual plates. Images were captured using the IVIS
Lumina image system (Xenogen), after 5 minutes incuba-
tion with substrate.
In vivo and ex vivo bioluminescent image quantification
To measure photon radiance, regions of interest (ROI)
were selected on the surface of the mice or the 24-well
plate using the automatic ROI. Bioluminescence was mea-
sured quantitatively by the Living Image® software, which
gave the total flux of photons or radiance (photons/second
from the surface) in each pixel, summed or integrated over
the ROI area, in a square centimeter (cm2) of the tissue.
These data were multiplied by one steradian (sr). The
photon radiance is displayed as the average radiance,
which is the sum of the radiance from each pixel inside
the ROI/number of pixels or superpixels (photons/sec/
cm2/sr) and the standard deviation of the pixel radiance
inside the ROI. Bioluminescence, acquired by the CCD
camera, was quantified by the Living Image® software using
three types of ROI: (1) the automatic ROI measurement
tool, which identifies bioluminescent emission automatic-
ally, considering a threshold of 20 to 28%; (2) the average
background ROI, which measures the background signal
in the area specified by the user and corrects the biolumin-
escent emission by subtraction; and (3) the subject ROI,
which identifies each animal in a image. Whenever neces-
sary, individual bioluminescent spots (foci) were summed
to get the photon radiance measurements (photons/sec/cm2/sr) of each region of the animal: abdomen, thorax,
paws, snout, ears, and urogenital region.
In the plate, bioluminescence acquired by the CCD
camera was obtained with two types of ROI, the auto-
matic measurement ROI, using a threshold of 25%, and
the average background ROI. After subtraction of back-
ground signal, bioluminescent radiance measurements
(photons/sec/cm2/sr) of spots distributed in the organ
were summed to get the total radiance measurement of
each organ: heart, rectum, gonads, fat tissue, intestines,
tail, ears, snout, hind limbs, and forelimbs. Thereafter,
the sum of bioluminescent radiance found in the whole
24-well plate, considered 100%, was used to estimate the
percentage of bioluminescence in each organ.
Histological analysis
Mice infected with Dm28c-luc, with Dm28c-WT and
uninfected control mice, were euthanized at the time
points indicated in the figure legends to collect heart,
rectum, gonads, fat tissue from gonadal depot, intestines,
tail, ears, snout, hind limbs, and forelimbs to be processed
as described elsewhere [20]. Briefly, fragments were fixed
using Millonig-Rosman solution [21], and 5 μm-thick
slices of paraffin-embedded samples were further processed
and stained using hematoxylin-eosin (HE). To obtain differ-
ent and representative regions of tissues, two 5 μm-thick
slices in an interval of 80 μm were collected per slide.
Qualitative analysis of tissues was based on cellular inflam-
matory infiltration and parasite nests.
Cytokine assays
Blood from mice infected with Dm28c-luc, with Dm28c-
WT and uninfected control mice, was obtained by cardiac
puncture using 3.8% sodium citrate and plasma was
separated after centrifugation, 1000 g/10 minutes at 4°C,
for cytokine analysis by flow cytometry (BD FACSCalibur™
flow cytometer) using the Cytometric Array kit (FlowCy-
tomix Mouse Th1/Th2 10plex) (eBiosciences, San Diego,
CA). This is a bead-based detection system for quantita-
tive detection of GM-CSF, IFN-γ, IL-1α, IL-2, IL-4, IL-5,
IL-6, IL-10, IL-17, and TNF-α. The evaluation was carried
out according to manufacturer instructions. Statistical
analyses were performed using the Excel software. Data
from cytokine analyses of Dm28c-WT and Dm28c-luc
were compared using a two-tailed unpaired t-test. Differ-
ences were considered significant if p values were < 0.05.
Results and discussion
Longitudinal evaluation of T. cruzi infection in mice
We showed in a previous publication that the genetically
modified bioluminescent epimastigote forms of Dm28c-luc
were stable after two years of cultivation in medium and
were able to differentiate into metacyclic trypomastigote
forms that infected LLC-MK2 cells in vitro. Transgenic
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culture, showed stable expression for six months (the
period tested) [12], allowing longitudinal evaluation of
the acute and chronic phases of infected mice.
To demonstrate that luciferase expression is stable in
all biological forms of transgenic parasites, Dm28c-luc
trypomastigotes were allowed to differentiate back to
epimastigotes. Bioluminescent emission was in the range
of epimastigotes maintained in LIT medium [12], display-
ing 20643 ± 1495 relative luminescence unit (RLU), as
evaluated in the microplate reader, Spectra Max2. For
intracellular amastigote evaluation, we used LLC-MK2cells
previously infected with 102 to 104 trypomastigotes. Thus,
Dm28c-luc trypomastigotes and LLC-MK2 cells infected
for 24 and 48 hours were evaluated for bioluminescent
emission using the IVIS Lumina system (Xenogen). Bio-
luminescence could be significantly detected in at least
1 × 103 trypomastigotes and intracellular parasites could be
detected in LLC-MK2 cells infected with as few as 5 × 10
2
trypomastigotes (Figure 1A), non infected LLC-MK2 was
used as negative control. Indeed, bioluminescence in in-
fected LLC-MK2 was 10 fold higher than bioluminescence
in trypomastigotes used to infect LLC-MK2 (Figure 1A).
Moreover, evaluation of in vitro infection of LLC-MK2
cells by optical microscopy of stained cells, suggests
that Dm28c-luc parasites have lower infection rates: (1)
after 24 hours, 20 to 10% for Dm28c-luc and 16 to 27%
for Dm28c-WT; (2) after 48 hours, 9 and 9.4% for Dm28c-
luc and 10 to 18% for Dm28c-WT. But once differentiated
into amastigotes, these cells retain normal proliferation,
comparable to wild type parasites, which ranged from 1.1
to 1.3 amastigotes per infected cell, for Dm28c-WT and
Dm28c-luc (n = 2).
As a first step to characterize infection in mice using
transgenic Dm28c-luc parasites, we compared blood para-
sitemia with that of mice infected with the Dm 28c-WT.
As shown in Figure 1B, mice infected with the wild type
strain showed a typical parasitemia curve for Dm28c,
which increased up to approximately 20 dpi (3.0 ± 1.0 ×
105 trypomastigotes/mL) and then gradually decreased.
Parasitemia peak and magnitude is in accordance with
previous publications [22,23]. However, in mice infected
with Dm28c-luc trypomastigote forms we found lower
levels of parasitemia (Figure 1), but those mice showed
active infection with patent levels of circulating parasites
at all time points. This observation indicates that the
course of infection may vary between Dm28c-WT and
Dm28c-luc parasites and indicates that caution may be
taken in the interpretation of results obtained with
transgenic parasites.
Blood cytokines evaluated on 20 dpi, showed no detect-
able levels of IL-1α, IL-2, IL-4, IL-17 (data not shown), or
IL-10 (Figure 2) in mice infected with Dm28c-WT and
Dm28c-luc strains of T. cruzi. Dm28c-WT strain inducedlow levels of IL-5, IL-6, TNF-α, and GM-CSF, but high
levels of IFN-γ (Figure 2), when compared to uninfected
control mice (data not shown). High levels of IFN-γ
have been described in the acute phase of the infection,
mainly produced by NK and CD4+ T lymphocytes [24].
Interestingly, the infection with Dm28c-luc induced a
different profile of cytokines, with lower levels of IFN-γ
and increased levels of IL-5 and IL-6 (Figure 2). IL-6 is an
important inflammatory cytokine, while IL-5, on the other
hand, is a T cell-derived cytokine that mainly promotes
proliferation, activation, and differentiation of eosinophils.
Indeed, the inflammatory process and hindpaw edema
caused by the Dm28c-luc transgenic parasite does not
reproduce the natural infection (personal communication,
Julio Scharfstein). It is possible that genetic manipulation
for transgenesis also affected the expression and/or im-
munogenicity of antigens of the parasite, which led to an
altered immunological response. It would be interesting to
make a cytokine kinetic analysis of the blood to evaluate
the profile of infection with Dm28c-luc throughout the
acute and chronic infection, but this is not the scope of
the present study.
To initiate longitudinal follow-up, BALB/c mice were
intraperitoneally infected with 1x106 trypomastigote forms
of Dm28c-luc. The same group of animals was evaluated
for a month, until the beginning of the chronic phase
of disease. Before each data acquisition, groups of three
animals were placed in the same position inside the IVIS
lumina chamber and were imaged in ventral (Figure
3–left panels), dorsal (Figure 3–central panels), and lat-
eral (Figure 3–right panels) position. One hour after infec-
tion, bioluminescence was observed in the peritoneal
cavity, near the site of inoculation, and in the urogenital
region (not shown). Twenty-four hours post inoculation
(1 dpi), the abdomen displayed an increase in the bio-
luminescent signal as a whole (Figure 3A–left and right
panels). The urogenital region showed prominent bio-
luminescence that was more visible in the lateral position
(Figure 3A–right panel). This pattern was observed until 7
dpi (Figures 3B,C–all panels, and Figure 4A), when bio-
luminescence reached a peak in the urogenital and ab-
dominal regions (Figure 3C–all panels, and Figure 4A).
On 7 dpi, bioluminescence was also observed in the dorsal
region and in the snout of the mice (Figure 3C–central
panel). On 11 dpi, the infection had disseminated to other
regions of the body, as seen via bioluminescent imaging
(not shown) and its quantification (Figures 4A and B). On
14 dpi, foci of bioluminescence were found distributed in
different regions of the head, including the nose and ears,
and in the tail and paws (Figure 3D–all panels, Figures 4A
and B). Bioluminescent foci were also detected in the
thorax (cardiac region) (Figures 3D and 4B). However, the
abdomen displayed a decreased bioluminescent signal,
which was even lower on 22 and 29 dpi (Figures 3E and F,
Figure 1 In vitro and in vivo parasite density curve. (A) In vitro bioluminescent measurement in the IVIS lumina system. Dm28c-luc trypomastigotes
(diamond); and intracellular parasite, after 24 hours (square) and 48 hours (triangle) post infection. Three independent experiments were performed.
(B) Parasitemia in mice infected with different T. cruzi populations. Animals were infected with 105 trypomastigotes of Dm28c-WT (open squares,
n = 10), or Dm28c-luc (solid squares, n = 15). Two independent experiments were performed.
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thorax (heart) of some mice was noticed (Figure 3 E–left
panel). Around 29 dpi, bioluminescence began to decline
in regions of the body and was restricted to certain foci
(Figure 3F–all panels, Figure 4B) such as the urogenital re-
gion (Figure 3 F–all panels, Figure 4A).
In vivo and ex vivo evaluation of acute and chronic
phases of T. cruzi infection
To evaluate the development of the pathology with this
new methodology, mice were also infected with a lower
parasite load of 1 × 105 trypomastigotes of Dm28c-luc
(n = 20) or Dm28c-WT (n = 20) strain. Each group of miceinfected with Dm28c-luc was evaluated by bioluminescent
imaging on 0, 1, 7, 14, 21, 28 and 180 dpi, until euthanized
for ex vivo evaluation of selected organs. The same pattern
of infection was observed via bioluminescence in the
abdomen, with subsequent migration of trypomastigotes
to the urogenital region 1 hour (0 dpi) after inoculation
(Figure 5A–all panels; Figure 6A). Twenty-four hours after
infection (1 dpi), bioluminescence was disseminated into
the peritoneal cavity (Figure 5B), and the urogenital region
displayed a lower bioluminescent signal (Figure 6A). In
some mice a punctuate site of infection, below the gonads,
was observed, which in some cases corresponded to the
terminal region of the rectum and portions of the large
Figure 2 Analyses of cytokines in the acute phase of infection.
Comparison of cytokine expression in the blood of mice infected
with Dm28c-WT (A) and Dm28c-luc (B) 20 dpi. Statistically significant
differences were observed for IL-5, IL-6, and IFN-γ when the p value
was <0.05 (t-test).
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(7 dpi), two bioluminescent peaks were observed: (1) at
the abdominal region; and (2) at the urogenital region
(Figure 5C, left and right panels; Figure 6A). Some dis-
persed foci of infection, however, were observed in other
regions of the body (Figure 6B). In the second week
(14 dpi), infection was distributed to regions of the
body, as evaluated by migration of bioluminescent par-
asites to the head, ears, paws, and tail (Figure 5D–all
panels) and measurements of acquired bioluminescent
signal (Figure 6B). However, the intensity of biolumin-
escence in the urogenital and abdominal region was
reduced at 14 dpi (Figure 6A). Considering that the dif-
fusion of light through the tissues provides a blurred
image, which prevents the precise identification of or-
gans that are infected, we dissected groups of mice to
confirm the precise location of infection. On 14 dpi three
mice were euthanized, the organs were collected and incu-
bated with substrate D-luciferin for ex vivo evaluation inthe IVIS® Imaging System. Organs of each mouse were col-
lected and grouped in one plate, bioluminescent radiance
was found in the whole 24-well plate, considered as 100%,
this was used to estimate the percentage of bioluminescence
in each organ. About 50% of bioluminescence was concen-
trated in the intestine, large and small intestines, and 30%
was distributed through the rectum, in the base of the tail,
gonads, and fat tissue (Figure 7A; Figure 8A). We also ob-
served 4% to 10% of bioluminescence in the snout of dis-
sected mice (Figure 8A). In one animal we observed
approximately 4% bioluminescence in the heart (Figure 8A).
In vivo evaluation on the third week (21 dpi) demon-
strated that bioluminescence was reduced in the thorax,
snout, ears, paws, and abdomen (Figure 5E–all panels;
Figures 6A and B), but the urogenital region displayed
stable bioluminescence (Figure 6A). Ex vivo evaluation of
infected organs by bioluminescent imaging demonstrated
that the colon, cecum, and rectum displayed patches of
bioluminescence that corresponded to 60% of biolumin-
escence found in the organs investigated in the plate
(Figure 7B; Figure 8B), followed by the testicles and tail,
which displayed 20% of bioluminescent emission; the
heart showed 3% (Figure 8B). On the fourth week (28
dpi) post inoculation, bioluminescence declined overall
in the body (Figure 5F–all panels, Figure 6A). Ex vivo
evaluation revealed that infection was mainly distributed
along the intestines and rectum, followed by the gonads
and tail (Figure 7C, Figure 8C). Chronically infected mice,
180 dpi, displayed some foci of infection in the uro-
genital region, which could be quantified (Figure 6A
and Figure 7E–all panels). To show that bioluminescent
emission is directly related to mice infected with Dm28c-
luc, images of mice infected with Dm28c-WT were in-
cluded as negative control (Figure 7F). Ex vivo evaluation
of dissected mice corroborated that bioluminescence was
predominant in the intestine, followed by the rectum and
tail (Figure 7D, Figure 8D). In other organs, such as the
heart, bioluminescence was undetected. Therefore, the
ex vivo evaluation supports the analysis made in vivo and
shows the precise sites of infection in the urogenital
region. The same profile of infection, with distribution
of bioluminescent parasites for some regions of the body
and its containment to the urogenital region, was observed
in BALB/c and Swiss mice (data not shown).
Genetically modified Dm28c-luc versus Dm28c-WT strain
After ex vivo evaluation of dissected organs by biolumin-
escent imaging, the tissues were embedded in paraffin,
stained with hematoxylin and eosin, and observed under
light microscopy (Figure 9). It was possible to observe the
pattern of Dm28c-luc and Dm28c-WT migration, support-
ing the bioluminescent imaging and demonstrating the
presence of amastigote nests in the terminal region of the
intestine (Figure 9B-H). Amastigote nests were observed
Figure 3 Follow-up of BALB/c mice infected with 106 trypomastigotes of transgenic Dm28c-luc strain. Bioluminescent images were
acquired for the same group of mice and one mouse is shown in the ventral (left panel), dorsal (central panel), and lateral (left panel) position
after 10 minutes of D-luciferin injection. The same mouse was evaluated after 1 dpi (A); 4 dpi (B), 7 dpi (C), 14 dpi (D), 22 dpi (E), 29 dpi (F). The
settings were binning small (small pixels), 10 seconds exposure. For bioluminescent signal quantification, images of mice in the ventral position were
evaluated. Subject ROI (square) was used to identify each individual in the image, average background ROI (circle, red dots) measured the background
bioluminescent signal which was used to correct the signal in the automatic measurement ROI (red line, circles). Scale bar of bioluminescent image
radiance (photons/sec/cm2/sr) of mouse in ventral position.
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strains, Dm28c-WT or Dm28c-luc (Figure 9B-H). How-
ever, oversized amastigote nests were observed on 14
dpi in the rectum and anal region of mice infected with
Dm28c-WT (Figure 9F) as compared to Dm28c-luc
(Figure 9B-C). From 21 to 28 dpi, the nests observed in
the terminal region of the intestine of mice infected with
Dm28c-WT decreased in size and in number of parasites
(Figure 9G-H). However, with Dm28c-luc parasites, amas-
tigote nests were more evident on the 28 dpi, which
suggest a delay in the development of infection in therectum and anal region of mice infected with Dm28c-luc
(Figure 9D-E). We also observed inflammatory foci in
close proximity to parasite nests in the tissues infected
with both strains, Dm28c-luc (Figure 9B) or Dm28c-WT
(Figure 9F). However, regions of intense lymphocyte infil-
trate were observed mostly in mice infected with Dm28c-
WT (Figure 9F-H). As described previously, myenteric
denervation has been observed in the acute phase of T.
cruzi infection. It seems that the mechanism involves
IFNγ, iNOS activation in the inflammatory foci in the
intestine, and NO production [25]. Therefore, in the
Figure 4 Follow up of BALB/c mice infected with 106 trypomastigotes of transgenic Dm28c-luc strain. In vivo quantification of
bioluminescent foci were performed in images of mice in the ventral position after subtracting the background signal from measurement ROI,
identified in the images by the automatic ROI tool (n = 5). Average and standard deviation of radiance, in the abdomen (diamond) and urogenital
region (triangle) (A), thorax (black square), snout (white square), paws (dark gray square), and ears (gray square) (B).
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http://www.parasitesandvectors.com/content/7/1/89infection with transgenic Dm28c-luc, the reduced levels
of IFNγ and lymphocyte infiltrate could reflect a less
deleterious effect in the colon and rectum.
Independent of strain tropism, previous publications
demonstrated a decline in intestinal mobility, evaluated
by charcoal elimination, in mice infected with different
T. cruzi strains, such as Dm28c, CL-Brener, Brazil, and
TcY. In the same work, it was demonstrated that Dm28c
interferes with intestinal mobility earlier than do other
strains, in the first week of infection [22].
In our study, the alterations observed in tissues of rectum
and anal sphincter are compatible with an inflammatory
process that could lead to disruption of the nervous system;
however, other tissues, glands, and regions of the intestine
(not investigated) could also be sites of infection, as
observed with naturally infected Opossum [26]. Thus,
the novel foci of infection in the acute and chronic
phases, such as (a) the rectum, (b) the anal sphincter,
(c) the testicle and its associated adipocyte tissues, and
(d) the base of the tail, could also have an impact in
the maintenance of infection in sylvatic, peri-domestic,
and domestic cycle and in the transmission of the disease
by routes not explored previously. In the case of Opossum,
contamination of environment and food with parasites
from the anal gland region has been shown [26]. Adipose
tissue was described as playing a role as a reservoir for
recrudescence of infection [5].
Considering that the heart is one of the most studied
and affected organ by T.cruzi infection, we performed
also an ex vivo evaluation of the heart by bioluminescent
imaging coupled to histological analysis, and compared
the myocardium infection caused by Dm28c-WT and
Dm28c-luc. In mice infected with Dm28-luc, biolumines-
cent emission could be detected until 28 dpi with a peak
at 14 dpi, and by histological analysis a few amastigotenests and scattered inflammatory cell infiltrates could
be observed at 14 dpi (Figure 9I and J). However, in
mice infected with Dm28c-WT, heart tissues showed
more amastigote nests and a few inflammatory infiltrates
(Figure 9L). In the third week after infection (21 dpi), a
few and small inflammatory infiltrates dispersed in the
cardiac fiber of mice infected with Dm28c-luc were
observed, some of them with amastigotes (Figure 9K).
However, in mice infected with Dm28c-WT a few but
clearly defined amastigote nests and inflammatory infiltrate
were observed (Figure 9M). At 28 dpi no amastigote nest
and inflammatory infiltrate was found, only discrete and
scattered inflammatory cells were observed in mice infected
with Dm28c-WT or Dm28c-luc (Figure 9N).
In the murine model, previous studies have demon-
strated the evolution of experimental T. cruzi infection
in heart tissues, with the presence of extracellular matrix
components and inflammatory infiltrate in the myocar-
dium, caused by Y strain in the acute phase of the disease.
In opposition, infection caused by Dm28c strain failed to
display inflammatory infiltrate and showed rare amastigote
nests [23], which suggested that different strains could
display different heart tissue responses [27,28].
In order to find other sites of parasite reservoirs and
infection, we evaluated tissues from the snout region such
as the cheeks and nose of infected mice by histopathology
analysis. In accordance with bioluminescent imaging,
on 14 dpi, parasite nests were also observed in the
snout, in muscle fibers of mice infected with each strain,
Dm28c-WT (Figure 9O) or with Dm28c-luc (Figure 9P).
Considering the organization of the tissue, which was
composed of collagen and connective tissues, it was more
difficult to evaluate the size of nests and to find parasite
nests on 21 and 28 dpi. It is important to point out that in
spite of the small size of amastigote nests in the muscle
Figure 5 (See legend on next page.)
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Figure 5 Follow-up of BALB/c mice infected with 105 trypomastigotes of transgenic Dm28c-luc strain. Bioluminescent images were
acquired for the same group of mice, three mice are shown in the ventral (left panel), dorsal (central panel), and lateral (left panel) position after
10 minutes of D-luciferin inoculation. The same three mice were evaluated one hour post infection 0 dpi (A); 1 dpi (B), 7 dpi (C), 14 dpi (D), 21
dpi (E), 28 dpi (F). The settings were binning medium (medium size pixels), 1 minute exposure. For bioluminescent quantification images of mice
in the ventral position were evaluated. Subject ROI (square) was used to identify each individual in the image, average background ROI (circle, red dots)
measured the background bioluminescent signal which was used to correct the signal in the automatic measurement ROI (red line, circles). Arrows
indicate urogenital region. Scale bar of bioluminescent image radiance (photons/ sec/ cm2/sr) of mice in ventral position.
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http://www.parasitesandvectors.com/content/7/1/89fibers of the snout, bioluminescent emission was above
the threshold and displayed enough photons to be cap-
tured and quantified, which confirms that firefly luciferase
expression in Dm28c-luc is stable and suitable for bio-
luminescent image studies.
Although amastigote nests were considerably more fre-
quent in animals infected with Dm28c-WT, the Dm28c-luc
strain was able to infect mice and displayed the same
pattern of infection. In vivo and ex vivo bioluminescent
imaging associated with histological analyses of tissue
sections corroborated that amastigote nests were larger
and more frequent in the rectum and anal region, if com-
pared to the nests found in the heart and other tissues,
and these sites of infection remained during the chronic
phase.
Another aspect that should be considered about bio-
luminescent imaging is that the methodology is able to
identify even small foci of infection in the organ, but
depending on the level of luciferase expression and the
tissues infected, the bioluminescent signal can be under
the detection limit. Due to the limitations of histological
techniques to evaluate residual and small foci of infections
in tissues and organs, additional techniques such as PCR
and qPCR should be considered to evaluate the presenceFigure 6 Follow up of BALB/c mice infected with 105 trypomastigotes
bioluminescent foci were performed in images of mice in the ventral posit
identified in the images by the automatic ROI tool (n = 12). Average and st
region (triangle) (A), thorax (black square), snout (white square), paws (dark
measurements made 1 hour after inoculation.of parasites in tissues and correlate bioluminescent image
with parasite burden.
Previous work has shown the use of bioluminescent
imaging in vivo to follow the parasite expressing firefly
luciferase within their mammalian host [29], and developed
a high-throughput bioluminescent imaging assay for drug
trials in mice inoculated with T. cruzi in the hind footpads
[30]. It was observed that the progression of infection in
mice infected with CL strain by intra peritoneal inoculation
was similar to our study, displaying a peak at 10 to 14 dpi,
but ex vivo bioluminescent imaging was restricted to a few
organs [29]. Thus, we performed longitudinal evaluation
with quantification of bioluminescent foci in vivo coupled
to a detailed ex vivo analyses of several regions and organs
until the chronic stage of infection, 180 dpi. Our study
gives new information and insights about the progression
and distribution of infection throughout tissues and foci
that are not usually explored but are important sites of
infection, and should be considered in studies with murine
models. If this pattern of infection is also related to the
strain Dm28c or to the site of inoculation, it is the scope
of our next work.
The biological and genetic variability of T. cruzi has
led to its classification into six groups or discrete typingof transgenic Dm28c-luc strain. In vivo quantification of
ion after subtracting the background signal from measurement ROI,
andard deviation of radiance of abdomen (diamond) and urogenital
gray square) and ears (gray square) (B). Dpi 0 corresponds to
Figure 7 Evaluation of T. cruzi infection by ex vivo and in vivo bioluminescent imaging of chronic infection. For ex vivo evaluation of
organs, images were acquired after incubation with D-luciferin in PBS in a plate, the settings were 5 minutes exposure and binning medium (pixels
size). For in vivo evaluation, bioluminescent images were acquired in ventral (left panel), dorsal (central panel), and lateral (left panel) position after
10 minutes of intra-peritoneal inoculation of D-luciferin. The settings were binning small (small pixels), 1 minute exposure. 14 dpi (A), 21 dpi (B), 28 dpi
(C), 180 dpi ex vivo (D), 180 dpi in vivo (E) and negative control (F). 1–heart, 2–rectum, 3–snout, 4–testicle and adipocyte, 5–forepaw, 6–hindpaw, 7–tail,
8–ear, 9–small intestine, 10–large intestine. For bioluminescent signal quantification, subject ROI (square) identified the animal in the image
of ventral position, average background ROI was placed in the animal or in the plate, on the liver, (Bkg, circle in red dots) to measure the
background bioluminescent signal which was used to correct the signal in an automatic measurement ROI (red line, circle), to produce a
background-corrected bioluminescent signal. Scale bar of bioluminescent image radiance (photons/ sec/ cm2/sr).
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as TcI; this strain was isolated from Didelphis marsupialis
in Venezuela, and the TcI genotype is widespread in
Colombia, Venezuela, and Central America, displaying
emerging importance [33,34]. Genotype analysis of isolatesFigure 8 Follow-up of BALB/c mice infected with 105 trypomastigotes
bioluminescent foci, identified in dissected organs in the plate, after subtra
in the images by the automatic ROI tool. Heart, snout, gonads,rectum, tail,
(white square), mice 2 (gray square), mice 3 (black square). Percentage of b
bioluminescent radiance found in the whole 24-well plate.from chagasic patients, domestic and wild mammals, and
triatomine bugs in Venezuela demonstrated that this group
of T. cruzi accounted for most of the isolates [35]. However,
the distribution of infection throughout the new foci of
infection such as, (a) the rectum, (b) the anal sphincter, (c)of transgenic Dm28c-luc strain. Ex vivo quantification of
cting the background signal (liver) from measurement ROI, identified
and intestine. 14 dpi (A); 21 dpi (B), 28 dpi (C), and 180dpi (D). Mice 1
ioluminescent radiance in each organ is related to total
Figure 9 Parasite localization in tissues of infected animals. Ex vivo evaluation of amastigote nests in the rectum and anal region (A-H), heart
(I-N) and in the snout (O-P) in BALB/c mice infected with 105 trypomastigotes of Dm28c-luc or Dm28c-WT. Rectum of uninfected mice, control
(A). Rectum of mice infected with transgenic Dm28c-luc stain (B-E): 14 dpi (B-C), 21 dpi (D), 28 dpi (E). Rectum of mice infected with Dm28c-WT
strain (F-H): 14 dpi (F), 21 dpi (G), 28 dpi (H). Heart of mice infected with transgenic Dm28c-luc stain (I-K and N): 14 dpi (I-J), 21 dpi (K) 28 dpi
(N). Heart of mice infected with Dm28c-WT (L-M): 14 dpi (L) and 21 dpi (M). Snout of mice infected with transgenic Dm28c-luc (O) and Dm28c-WT
strain (P). Arrows indicate amastigote nests and asterisks inflammatory infiltrate.
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in the population affected by Chagas disease and during
treatment, but can have a role in disease prognosis.Conclusion
The present work demonstrated that bioluminescent im-
aging associated with microscopic examination of tissue
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evaluation of infection in the murine model.
The genetically modified strain is stable, and suitable
for follow-up studies in vivo in the murine model, whose
intensity of bioluminescent emission increases in accord-
ance with the inoculum used to infect—106 (Figures 3A
and B) or 105 (Figures 5A and B). The fact that the trans-
genic strain could be less lethal, but able to evolve into
the chronic phase for 6 months to one year (not shown),
can be an advantage for drug trials in vivo. This method-
ology brought, for the first time, new information about
the progression and dynamics of infection, detecting new
sites of infection.
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